US EditionCorFlow Therapeutics to begin pivotal trial of CoFl system for heart attack care
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
CorFlow Therapeutics gains US FDA approval for IDE trial - Cardiovascular News
CoFI CorFlow Therapeutics has announced that the US Food & Drug Administration (FDA) has approved the company’s technology for investigational device exemption (IDE), allowing a pivotal clinical trial to begin at US hospitals. CorFlow will prepare clinical trial sites to receive CorFlow systems, undergo training and begin enrolling patients being treated for heart attacks. The IDE pivotal trial—MOCA-II—is intended to prospectively validate the d…
CorFlow Therapeutics to begin pivotal trial of CoFl system for heart attack care
CorFlow Therapeutics is set to initiate a pivotal trial of its CorFlow CoFl system across US hospitals for heart attack.The post CorFlow Therapeutics to begin pivotal trial of CoFl system for heart attack care appeared first on Medical Device Network.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
